Tepotinib Hydrochloride Hydrate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tepotinib Hydrochloride Hydrate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
40
Registered trials
81
Result records
2
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Tepotinib Hydrochloride Hydrate can convert its Small molecule drug profile and c-Met biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tepotinib Hydrochloride Hydrate (query alias: tepotinib) |
|---|---|
| Modality / target | Small molecule drug; c-Met; c-Met inhibitors |
| Highest global status | Approved |
| Originator | Merck Serono SA |
| Active developers | Merck KGaA, Merck Healthcare Pty Ltd., Merck Serono (Beijing) Pharmaceutical R&D Co., Ltd. |
The MCP disease footprint includes MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer, c-Met positive non-small cell lung cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| JPRN-jRCT1031260225 | Phase 3 | 募集中 | 100 | Overall survival |
| NCT07619339 | Phase 1 | Recruiting | 16 | Dose finding |
| CTR20255024 | Not Applicable | 已完成 | 32 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Profiling patients with MET exon 14 (METex14) skipping NSCLC with a sustained clinical benefit to tepotinib in VISION.
Phase 2; n=26; evaluation: Positive. Reported fields: AE = In 12 patients who discontinued treatment, reasons for discontinuation were: adverse events (5 patients [peripheral edema in 2 patients]), disease progression per investigator (3 patients), non-compliance (1 patient), consent withdrawal (1 patient), and other reasons (2 patients).
1030P - Real-world efficacy and safety of tepotinib in non-small cell lung cancer patients harboring MET exon 14 skipping mutations: A retrospective, multicenter study in taiwan (MomEnTum)
Not Applicable; n=55; evaluation: Positive. Reported fields: ORR = 40.0 % ; ORR = 36.36 % ; ORR = 20.0 %
1075eP - De novo and acquired MET amplification in patients (pts) with non-small cell lung cancer (NSCLC) treated with tepotinib: Results from a real-world data analysis in Australia
Not Applicable; n=16; evaluation: Positive. Reported fields: Median (range) DoT = 16.0 month ( 3 - 24); Median (range) DoT = 11.0 month ( 2 - 26)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tepotinib Hydrochloride Hydrate addresses MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer, c-Met positive non-small cell lung cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 2 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2025-03-26 | 罗氏制药与默克达成战略合作！进一步拓展中国肺癌治疗版图 | Approved | Financial terms not disclosed |
| 2021-11-17 | Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock’s OncoCompass Target™ | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Tepotinib intermediate and preparation method thereof”. The milestone feed surfaced a patent-application signal described as “Treatment with an antibody that binds EGFR and cmet”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
